Metronomic Chemotherapy in Prostate Cancer

Despite the significant expansion of the therapeutic armamentarium associated with the introduction of novel endocrine therapies, cytotoxic agents, radiopharmaceuticals, and PARP inhibitors, progression of metastatic castration-resistant prostate cancer (mCRPC) beyond treatment options remains the l...

Descripción completa

Detalles Bibliográficos
Autores principales: Wysocki, Piotr J., Lubas, Maciej T., Wysocka, Malgorzata L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143236/
https://www.ncbi.nlm.nih.gov/pubmed/35628979
http://dx.doi.org/10.3390/jcm11102853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143236/
https://www.ncbi.nlm.nih.gov/pubmed/35628979
http://dx.doi.org/10.3390/jcm11102853

Ejemplares similares